Joel Neal, MD, PhD
Academic Appointments
- Assistant Professor - Med Center Line, Medicine - Oncology
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Stanford Comprehensive Cancer Center 875 Blake Wilbur Dr CC 2220 MC 5826 Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 498-5800
- Academic Offices
Personal Information Tel (650) 725-3081Alternate Contact Traci Foster Administrative Assistant Tel Work 650-725-3081Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Thoracic Oncology
- Thoracic Oncology
- Lung Cancer
- Medical Oncology
Professional Education
| Board Certification: | Medical Oncology, American Board of Internal Medicine (2010) |
| Medical Education: | Feinberg School of Medicine - Northwestern University IL (05/2004) |
| Fellowship: | Dana-Farber Cancer Institute MA (08/2010) |
| Residency: | Beth Israel Deaconess Medical Center MA (06/2007) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (2007) |
Graduate & Fellowship Program Affiliations
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
Non-small cell lung cancer (NSCLC) has historically been treated with combination chemotherapy. Over the last few years, molecular testing of NSCLC has revealed the presence of driving oncogenic mutations in a subset of tumors of adenocarcinoma histology, including EGFR, KRAS, and ALK. While chemotherapy is still effective for these patients, targeted therapies appear to be more specific with fewer side effects. For example, erlotinib treatment of EGFR mutant tumors results in better response rates and progression-free survival times than chemotherapy, and the investigational drug crizotinib is targeted against tumors harboring ALK translocations. My clinical and research interest is to apply evolving technologies to the diagnosis, characterization, and individualized treatment of NSCLC.
Clinical Trials
- Recruiting BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
- Recruiting Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Recruiting Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
- Not Recruiting A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
- Recruiting Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer
Publications
- A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab. J Thorac Oncol. 2013; (2): e17-8
- A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib. J Natl Compr Canc Netw. 2013; (4): 389-94
- Aflibercept in lung cancer. Expert Opin Biol Ther. 2013; (1): 115-20
- A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J Thorac Oncol. 2012; (10): 1602-8
- Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol. 2012; (18): 2280-2
- First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. Biologics. 2012: 337-45
Help
Trial Administration